hotspot -WSS

hotspot

author：knowledge 2025-09-27 09:44:36 - browse：673

An eye emerges from lines of binary codes — health tech coverage from STAT — Adobe

Investors are starting to back startups that offer privacy and security services to bolster health AI products already on the market while they wait for crucial safety and privacy regulations to take shape.

Though health leaders are racing to deploy generative AI products that can automatically transcribe doctor-patient conversations during medical appointments or churn through massive repositories of scientific research, they’re still flummoxed about how to measure their quality. Cybersecurity experts have warned that indiscriminately hooking third-party apps up to health system networks could expose sensitive data to hackers as ransomware attacks surge, and regulators and industry groups are rushing to set standards for responsible AI use.

Several government agencies and industry groups are working on rules and recommendations for avoiding bias and safety hazards within medical AI, but hospitals and startups are still in the dark about what exactly those will require and who’ll eventually be liable for any harm caused. It could be months, or even years, before these overlapping rules from multiple federal agencies are in place, and those rules might still change as the technology evolves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Pig kidney works a record two months in donated body

knowledge

Wikipedia

leisure time

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

FDA proposes changes to key medical devices approval pathway

Hospitals consider fixing cancer drug shortages on their own

How medical schools plan to diversify without affirmative action

New weight loss drugs vying to be the next Wegovy or Mounjaro

Pfizer plans to depart BIO

focus

hotspot

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

FDA needs staff influx to meet gene therapy needs, Marks says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Moonlake's readout produced a cash windfall. Risks remain

Long Covid needs a new name — and a new frame

Dobbs anniversary: the lost opportunity of abortion as health care

IRA could hurt research into orphan drugs for rare diseases

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT letters to the editor on burnt

hotspot

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Long Covid needs a new name — and a new frame

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Americans' trust in science, scientist continues decline: Report

Diverse clinical trials: Why aren’t we there yet?

SCOTUS to consider access to abortion pill mifepristone

knowledge

Wikipedia

leisure time

leisure time